NEXGEL Expands STADA Partnership with $1 Million Investment for Digestive Enzyme and Scar Treatment Products
Key Insights
NEXGEL (search), Inc. announced an expanded collaboration with European pharmaceutical leader STADA Arzneimittel AG to develop and launch digestive enzyme formulas (search) and advanced scar and stretch mark care solutions (search) in North America.
STADA will provide $1 million in non-dilutive capital to support product development, launch activities, and marketing initiatives for these new health product lines.
The partnership leverages NEXGEL (search)'s expertise in advanced hydrogel (search) technologies and STADA's established presence in consumer health markets across over 100 countries.
NEXGEL (search), Inc. (NASDAQ: NXGL) announced an expanded collaboration with European pharmaceutical and consumer health leader STADA Arzneimittel AG, securing $1 million in non-dilutive capital to fuel the development and launch of innovative digestive enzyme formulas (search) and advanced solutions for scar and stretch mark care in North America.
The Langhorne, Pennsylvania-based hydrogel (search) technology company will leverage this financial support to accelerate product development, launch activities, and marketing initiatives as it enters high-demand wellness categories. The partnership expansion builds on NEXGEL (search)'s existing relationship with STADA, which operates in over 100 countries worldwide.
Strategic Partnership Details
"This next phase of our partnership reflects a shared outlook that there is an opportunity in bringing these health solutions to consumers across North America," said Adam Levy, Chief Executive Officer of NEXGEL (search). "We are grateful for STADA's financial support, which will accelerate our joint go-to-market strategy."
The collaboration focuses on two key product categories: digestive enzyme formulations and advanced scar and stretch mark treatment solutions. These product lines represent NEXGEL (search)'s continued expansion into consumer wellness markets, utilizing the company's expertise in ultra-gentle, high-water-content hydrogel (search) technologies.
Company Positioning and Market Strategy
NEXGEL (search) has developed and manufactured electron-beam, cross-linked hydrogels for over two decades, establishing itself as a leading provider of healthcare, beauty, and over-the-counter products. The company's portfolio includes established brands such as SilverSeal (search)®, Hexagels (search)®, Turfguard (search)®, Kenkoderm (search)®, and Silly George (search)®, alongside strategic contract manufacturing relationships with leading consumer healthcare companies.
The agreement underscores NEXGEL (search)'s strategy of aligning with established global partners to scale its innovative offerings. For STADA, the partnership strengthens its position in the growing North American consumer health market, complementing its three-pillar strategy of consumer healthcare products, generics, and specialty pharmaceuticals.
STADA's Global Presence
STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, achieved group sales of €4,059 million in financial year 2024, with adjusted constant-currency earnings before interest, taxes, depreciation and amortization of €886 million. The company employed 11,649 people worldwide as of December 31, 2024.
With this financial boost and expanded collaboration, NEXGEL (search) is positioning itself to capture new market segments and further its reputation for delivering specialized health and wellness solutions backed by advanced material science. The partnership represents a strategic alignment between NEXGEL's innovative hydrogel (search) technology platform and STADA's established global distribution capabilities in consumer health markets.